Related Experiment Video

Updated: Aug 8, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

The use of thalidomide in androgen-independent prostate cancer

Michael C Cox1, William L Dahut, William D Figg

  • 1Clinical Pharmacology Research Core, Medical Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

Urologic Oncology
|May 9, 2006
PubMed

Insights

Thalidomide shows promise for treating advanced prostate cancer. Further research is needed to explore its potential in improving outcomes for patients with this difficult-to-treat cancer.

Area of Science:

  • Oncology
  • Cancer Research
  • Urology

Background:

  • Prostate cancer affects over 200,000 men annually, with a significant percentage developing incurable advanced disease.
  • Current treatments, including docetaxel, offer improved survival but do not provide a cure for metastatic prostate cancer.
  • The concept of inhibiting angiogenesis, or new blood vessel formation, presents a potential therapeutic strategy.

Purpose of the Study:

  • To review the efficacy of thalidomide in treating androgen-independent prostate cancer.
  • To summarize clinical trial results investigating thalidomide at the National Cancer Institute.

Main Methods:

  • Review of existing literature on thalidomide's use in prostate cancer.
  • Analysis of data from clinical trials conducted at the National Cancer Institute.

Main Results:

  • Thalidomide has been investigated as a treatment for advanced prostate cancer.
  • Clinical trials at the National Cancer Institute have evaluated thalidomide's impact on patient outcomes.

Conclusions:

  • Thalidomide represents a potential therapeutic option for androgen-independent prostate cancer.
  • Further investigation into angiogenesis inhibitors like thalidomide is warranted for advanced prostate cancer treatment.

More Related Videos

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Concept Videos

Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...